Early detection of neurodegeneration could transform preventive medicine, particularly given that recently approved Alzheimer's therapies work best when started before cognitive decline becomes apparent. Most current diagnostic approaches require expensive brain imaging or invasive procedures, creating barriers to widespread screening. A novel immuno-infrared sensor platform addresses this challenge by identifying protein misfolding patterns in blood samples, potentially catching Alzheimer's and Parkinson's disease years before symptoms emerge. The technology combines antibody-based protein capture with quantum cascade laser spectroscopy to measure amide I absorbance, which reflects the degree of protein structural abnormalities characteristic of these neurodegenerative conditions. The sensor uses functionalized crystal surfaces where specific antibodies concentrate target biomarker proteins while blocking layers prevent false positive readings. This approach represents a significant advance in accessibility compared to current methods. Blood-based screening could enable population-wide surveillance programs, identifying at-risk individuals when lifestyle interventions remain highly effective and disease-modifying treatments can still alter trajectory. The potential for routine screening parallels how cholesterol testing revolutionized cardiovascular prevention. However, several hurdles remain before clinical implementation. The technology requires validation across diverse populations and longer-term studies to establish sensitivity and specificity benchmarks. False positives could create unnecessary anxiety, while the clinical significance of very early protein misfolding detection needs clearer definition. Additionally, healthcare systems would need substantial infrastructure changes to handle large-scale screening programs and provide appropriate follow-up care for positive results.